Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Helena Hohtari, MD, Shady Awad, MD, Olli Dufva, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Satu Mustjoki, MD PhD, Kimmo Porkka, MD PhD

Blood (2018) 132 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2018-99-110610

Published: 2018

Journal Articles

Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?

Pierre-Edouard Debureaux, Myriam Labopin, MD PhD, Simona Lapusan, MD, Francoise Isnard, PhD, Rosa Adaeva, Agnès Bonnin, Pierre Hirsch, MDPhD, Francois Delhommeau, MD PhD, Giorgia Battipaglia, MD, Remy Duléry, MD, Federica Giannotti, MD, Florent Malard, MDPhD, Annalisa Ruggeri, MD, Anne Vekhoff, Ollivier Legrand, MD PhD, Mohamad Mohty, MD PhD, Eolia Brissot, MDPhD

Blood (2017) 130 (Supplement 1): 4603.

https://doi.org/10.1182/blood.V130.Suppl_1.4603.4603

Published: 2017

Journal Articles

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

Etienne Paubelle, MD PhD, Sophie Ducastelle, MD, Helene Labussiere, MD, Franck E. Nicolini, MD PhD, Fiorenza Barraco, MD, Adriana Plesa, Gilles A. Salles, Eric Wattel, MD PhD, Xavier Thomas, MD PhD

Blood (2016) 128 (22): 4003.

https://doi.org/10.1182/blood.V128.22.4003.4003

Published: 2016

Journal Articles

An Impdh Inhibitor, FF-10501 Possesses Activating Effects on Myeloid Differentiation As Well As Anti-Proliferation

Michiko Ichii, MD PhD, Motohiko Murase, MSc, Kensuke Komatsu, PhD, Motoki Saito, PhD, Jun Toda, MD, Kenji Oritani, MD PhD, Hiroyuki Iwamura, PhD, Yuzuru Kanakura, MD PhD

Blood (2015) 126 (23): 3679.

https://doi.org/10.1182/blood.V126.23.3679.3679

Published: 2015

Journal Articles

Low-Dose Arsenic Trioxide Combined with Aclacinomycin a Synergistically Enhance the Cytotoxic Effect on Human Acute Myelogenous Leukemia KG-1a Cell Line By the Induction of Apoptosis

Yongbin Ye, Xiaojun Xu, Mingwan Zhang, Dafa Qiu, Xiaochun Bai, Jing Wang, Guangyang Weng, Zhou Ruiqing, Ziwen Guo, Huiqing He, Wenfang Yi, Xin He, Guo Kunyuan

Blood (2014) 124 (21): 5303.

https://doi.org/10.1182/blood.V124.21.5303.5303

Published: 2014

Journal Articles

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Randeep Sangha, Andrew Davies, PhD, Nam H. Dang, MD, PhD, Michinori Ogura, MD, PhD, David A. MacDonald, MD, Angela Volkert, Revathi Ananthakrishnan, Kenneth Luu, Joseph P. Boni, PhD, Erik Vandendries, MD, Yeow-Tee YT Goh, MD

Blood (2013) 122 (21): 1821.

https://doi.org/10.1182/blood.V122.21.1821.1821

Published: 2013

Journal Articles

An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data

Michinori Ogura, MD, PhD, Kiyohiko Hatake, Andrew Davies, MD, Michael Crump, MD, FRCPC, Kensei Tobinai, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, Shaw-Ling Wang, Taro Ishibashi, Luisa Paccagnella, Erik Vandendries, David A MacDonald

Blood (2012) 120 (21): 1633.

https://doi.org/10.1182/blood.V120.21.1633.1633

Published: 2012

Journal Articles

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Michinori Ogura, Toshiki Uchida, David A MacDonald, Kiyohiko Hatake, Andrew Davies, Randeep Sangha, Michael Crump, MD, FRCPC, Catherine Thieblemont, MD, Taro Ishibashi, Steven Hua, Luisa Paccagnella, Erik R Vandendries, MD, PhD, Yukio Kobayashi, Kensei Tobinai, MD

Blood (2011) 118 (21): 3715.

https://doi.org/10.1182/blood.V118.21.3715.3715

Published: 2011

Journal Articles

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Andre Goy, MD, Joseph Leach, MD, W. Christopher Ehmann, MD, Kiyoshi Ando, MD, PhD, Kiyohiko Hatake, MD, PhD, Kensei Tobinai, MD, PhD, Tatyana Feldman, MD, Steven Hua, Angela DG Volkert, Erik R. Vandendries, MD, PhD, Michinori Ogura, MD, PhD

Blood (2010) 116 (21): 430.

https://doi.org/10.1182/blood.V116.21.430.430

Published: 2010

Journal Articles

EORTC 21012: Phase II Multicentre Study of Caelyx™ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.

Reinhard Dummer, Sean Whittaker, Baktiar Hasan, Juergen C Becker, Michael Weichenthal, Rudolf Stadler, Matthias Karrasch, Martine Bagot, Robert Knobler, Maria Bernengo

Blood (2010) 116 (21): 2823.

https://doi.org/10.1182/blood.V116.21.2823.2823

Published: 2010

Journal Articles

Phase I and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC- 544) as a Single Agent in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab.

Kensei Tobinai, MD, PhD, Michinori Ogura, MD, PhD, Kiyohiko Hatake, MD, PhD, Yukio Kobayashi, MD, PhD, Takashi Watanabe, MD, PhD, Toshiki Uchida, MD, PhD, Masanobu Kasai, MD, Masahiro Yokoyama, MD, Yasuhito Terui, MD, PhD, Chiho Ono, Masanao Akiyama, Junko Ohata, MD, PhD

Blood (2008) 112 (11): 1565.

https://doi.org/10.1182/blood.V112.11.1565.1565

Published: 2008

Journal Articles

Hypersensitivity Reaction of Gemtuzumab Ozogamicin (Mylotarg™) Associated with Platelet Transfusion: Two Case Reports.

Amr Hanbali, MD, Ira Wollner, MD, Klodiana Neme, PharmD, Cynthia Ulreich, RN BSN OCN

Blood (2006) 108 (11): 4549.

https://doi.org/10.1182/blood.V108.11.4549.4549

Published: 2006

Journal Articles

FLAG-(IDA)-Mylotarg in the Therapy of Relapsed and Refractory Acute Myeloid Leukemia.

Francesco Fabbiano, MD, Francesca Mondello, MD, Silvana Magrin, MD, Rosaria Felice, MD, Carla Marino, MD, Diamante Turri, MD, Salvatore Mirto, MD.

Blood (2005) 106 (11): 4627.

https://doi.org/10.1182/blood.V106.11.4627.4627

Published: 2005

Journal Articles

Gemtuzumab Ozogamicin (Mylotarg ® ) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML).

Xavier Thomas, Quoc-Hung Le, Emmanuelle Tavernier, Samira Mahmoudi, Youcef Chelghoum, Franck Nicolini, Anne Thiebaut, Jacques Troncy, Daniela Revesz, Mohamed Elhamri, Mauricette Michallet

Blood (2005) 106 (11): 4598.

https://doi.org/10.1182/blood.V106.11.4598.4598

Published: 2005

Journal Articles

Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).

Anjali Advani, Eva Giné, Christian Gisselbrecht, Ama Rohatiner, Steven Rosen, Mitchell Smith, Joseph Boni, Chantal Lejeune, Hemant Patel

Blood (2005) 106 (11): 230.

https://doi.org/10.1182/blood.V106.11.230.230

Published: 2005

Journal Articles

Gemtuzumab Ozogamicin (Mylotarg R ) as Primary Induction Therapy for Elderly Patients with Acute Myeloid Leukemia: A Phase II Trial.

Lisa A. Kujawski, MD, Elaina M. Gartner, MD, Irene Ryan, PA-C, Kent Griffith, Harry P. Erba, MD, PhD

Blood (2004) 104 (11): 4508.

https://doi.org/10.1182/blood.V104.11.4508.4508

Published: 2004

Journal Articles

Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor

Justin Stebbing, Brian Gazzard, Simon Portsmouth, Frances Gotch, Louise Kim, Mark Bower, Sundhiya Mandalia, Robert Binder, Pramod Srivastava, Steve Patterson

Blood (2003) 102 (5): 1806–1814.

https://doi.org/10.1182/blood-2003-03-0891

Published: 2003

NARROW

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

An Impdh Inhibitor, FF-10501 Possesses Activating Effects on Myeloid Differentiation As Well As Anti-Proliferation

Low-Dose Arsenic Trioxide Combined with Aclacinomycin a Synergistically Enhance the Cytotoxic Effect on Human Acute Myelogenous Leukemia KG-1a Cell Line By the Induction of Apoptosis

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

EORTC 21012: Phase II Multicentre Study of Caelyx™ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.

Phase I and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC- 544) as a Single Agent in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab.

Hypersensitivity Reaction of Gemtuzumab Ozogamicin (Mylotarg™) Associated with Platelet Transfusion: Two Case Reports.

FLAG-(IDA)-Mylotarg in the Therapy of Relapsed and Refractory Acute Myeloid Leukemia.

Gemtuzumab Ozogamicin (Mylotarg ® ) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML).

Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).

Gemtuzumab Ozogamicin (Mylotarg R ) as Primary Induction Therapy for Elderly Patients with Acute Myeloid Leukemia: A Phase II Trial.

Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only